ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1212

Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1247

Relation of Measures of Pain Sensitization to Widespread Pain

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1329

Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1242

Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1215

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1469

Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1147

Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1379

Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1398

Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1563

RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0940

Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling

(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0995

Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1286

Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus

(1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1413

Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0918

Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)

(0916–0933) Innate Immunity Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].